Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)

NCT03263962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 502

Last updated 2018-02-05

No results posted yet for this study

Summary

To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with congestive heart failure and preserved systolic function after 12 years of evaluation.

Conditions

  • Cardiac Heart Failure Patients

Interventions

DRUG

Canrenone

Evaluation of canrenone therapy in patients with CHF

Sponsors & Collaborators

  • University of Pavia

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-13
Primary Completion
2017-09-10
Completion
2017-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03263962 on ClinicalTrials.gov